Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a tiny dose of a diabetes drug help people with HIV avoid weight regain?

NCT ID NCT07325500

First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 20 times

Summary

This study tests whether a very low dose of semaglutide (a drug used for weight loss and diabetes) can help people with HIV maintain weight loss and improve heart health. Thirty participants will first receive a standard dose for 12 weeks, then half will get a low maintenance dose for 48 weeks while the other half stops. The goal is to see if the low dose prevents weight regain and is well tolerated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WEIGHT GAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.